Dr. Peter “Pete” Killcommons has served as CEO of Medweb for more than two decades. His company specializes in providing teleradiology and telemedicine services, and his expertise in the field led to his appointment as a keynote speaker at the First Armenian International Telemedicine Congress in October 2011. Dr. Peter Killcommons is also a member of the American Telemedicine Association (ATA).
The ATA recently applauded President Trump’s October 2017 declaration in which he allowed the Department of Health and Human Services (HHS) to lift legal restrictions on prescribing controlled substances using telemedicine. Under the Ryan Haight Act, telemedicine professionals had been restricted from prescribing opioid treatment options, such as naloxone, via telemedicine. The lift on the ban is effective for 90 days but can be extended by another presidential declaration.
The ATA hopes that this action will spur the DEA to create a special registration provision for telemedicine providers. In his comments, ATA president Dr. Peter Yellowlees praised the move, calling it an important first step toward helping telemedicine physicians better treat opioid addiction.
The ATA recently applauded President Trump’s October 2017 declaration in which he allowed the Department of Health and Human Services (HHS) to lift legal restrictions on prescribing controlled substances using telemedicine. Under the Ryan Haight Act, telemedicine professionals had been restricted from prescribing opioid treatment options, such as naloxone, via telemedicine. The lift on the ban is effective for 90 days but can be extended by another presidential declaration.
The ATA hopes that this action will spur the DEA to create a special registration provision for telemedicine providers. In his comments, ATA president Dr. Peter Yellowlees praised the move, calling it an important first step toward helping telemedicine physicians better treat opioid addiction.
RSS Feed
